Piper Jaffray Raises PT on Theravance to $35

by Juan Lopez, Benzinga Staff Writer
January 5, 2012 6:48 AM | 7 seconds read |
Piper Jaffray has raised the price target on Theravance THRX from $31 to $35 and maintains its Overweight rating.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetPre-Market OutlookAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!